Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Beam ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Growth Drivers of The Gene Therapy Industry As per IMARC, the US gene therapy market size has been pegged at US$1,312.2 million in 2024. The market should reach US$3,697.8 million by 2033.

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

Beam Therapeutics Inc. (BEAM) shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

The issue is that six years ago, Prime appeared to sign away its rights to create AATD treatments to another company it has long collaborated with, Beam Therapeutics.

Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD. BEAM has a long cash runway, and its ...

EDT Cathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics (BEAM) todayStay Ahead of the Market: Discover outperforming ...

Beam Therapeutics Inc.’s BEAM share price has surged by 9.89%, which has investors questioning if this is right time to sell.

Beam Therapeutics specializes in developing base-edited therapies for rare diseases and cancers. The company’s proprietary base editing platform allows for precise genetic modifications without ...